Get the Stockscreener App
3.27
5.22%
-0.18
Cellectis Adr stock is traded at $3.27, with a volume of 47,654.
It is down -5.22% in the last 24 hours and down -6.57% over the past month.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
See More
Previous Close:
$3.45
Open:
$3.3
24h Volume:
47,654
Relative Volume:
0.34
Market Cap:
$239.35M
Revenue:
$5.15M
Net Income/Loss:
$-65.35M
P/E Ratio:
-2.4222
EPS:
-1.35
Net Cash Flow:
$-20.85M
1W Performance:
-9.92%
1M Performance:
-6.57%
6M Performance:
+105.53%
1Y Performance:
+81.67%
1-Day Range:
$3.21
$3.4425
1-Week Range:
$3.21
$3.79
52-Week Range:
$1.10
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Compare CLLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.32 | 346.12M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.83 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.76 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.96 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.94 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| May-18-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-06-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-08-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-08-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-28-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-16-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-19-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Robert W. Baird | Outperform |
| Mar-06-20 | Downgrade | Goldman | Neutral → Sell |
| Oct-30-19 | Resumed | Guggenheim | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| May-24-19 | Resumed | Citigroup | Neutral |
| Mar-14-19 | Initiated | William Blair | Outperform |
| Dec-19-18 | Initiated | Goldman | Neutral |
| Jul-16-18 | Initiated | Barclays | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Sep-05-17 | Downgrade | SunTrust | Buy → Hold |
| Sep-05-17 | Reiterated | Wells Fargo | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Feb-28-17 | Initiated | Wells Fargo | Outperform |
| Apr-05-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Jul-20-15 | Initiated | BofA/Merrill | Buy |
| Apr-20-15 | Initiated | Jefferies | Buy |
| Apr-20-15 | Initiated | Piper Jaffray | Overweight |
View All
Cellectis Adr Stock (CLLS) Latest News
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail
Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines
Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Cellectis reports promising data for lasme-cel in r/r B-ALL - Investing.com
Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Cellectis’s SWOT analysis: gene therapy firm’s stock poised for growth? - Investing.com
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
European Stocks In The US Close The Week Mostly Steady - Finimize
Biotech And Tech Firms Drive Gains For European ADRs - Finimize
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates - ADVFN Brasil
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal moment - Investing.com
Earnings call transcript: Cellectis Q2 2025 earnings miss drives stock down 13% - Investing.com
Cellectis earnings missed by $0.02, revenue topped estimates - Investing.com India
Cellectis earnings missed by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
European Stocks Dip As US Holders Turn Cautious - Finimize
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
European ADRs Inch Higher As Drugmakers Shine - Finimize
Cellectis shares surge 66% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
European Stocks Falter On Wall Street As ADR Index Drops - Finimize
European Equities Slip While Biopharma Stocks Shine - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com
Cellectis Adr Stock (CLLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):